EGFR and Familial prostate cancer: The feasibility and efficacy of the inhibitory effects of LRIG1 on tumor through inhibiting EGFR signaling activity have been studied in renal cancer, glioma, squamous cell carcinoma of skin, colorectal cancer and prostate cancer [19-23].